Vaccines 1

• FC 07-01 • Evaluation of mucosal and systemic immunoglobulin A/G responses one year after 3 doses of the human papillomavirus- 16/18 ASO4- adjuvanted vaccine See abstract > A. A.K. GONCALVES • FC 07-02 • Advancing HPV vaccine delivery: 12 priority research gaps See abstract > N. N.T. BREWER • FC 07-03 • Trends in prevalence of human papillomavirus types and the impact of nonavalent vaccination: analysis on 13,665 patients over a 18-year study period See abstract > G. G. BOGANI • FC 07-04 • Design, baseline findings and HPV genotypes from a randomized controlled trial with the quadrivalent HPV vaccine comparing a 2-dose (0,6 months) to an extended ( 0,6,60 months) schedule: ICI-VPH study See abstract > M-H. Marie-Hélène MAYRAND • FC 07-05 • Efficacy of HPV vaccine in young women in Colombia after five years of its introduction See abstract > C. Carolina Wiesner • FC 07-06 • Quantifying the impact of HPV vaccination of 12 year old girls on cervical disease and cytology performance See abstract > T. T. PALMER • FC 07-07 • Cellular immune responses six years following reduced-dose quadrivalent HPV vaccine in adolescent Fijian girls See abstract > Z. Z.Q. TOH • FC 07-08 • The efficacy of vaccine prophylaxis of HPV-associated diseases in the Moscow region See abstract > N. Nina Zarochentseva • FC 07-09 • Hazard of complex regional pain syndrome (CRPS) following HPV vaccination among adolescents in the United States See abstract > N. N. Vielot • FC 07-10 • Systematic causality assesment of adverse events following HPV vaccination in Italy See abstract > D. D. MARTINELLI